Novel, specific inhibitors of acute and chronic inflammation

Abstract

The present invention relates to the use of one or more of the compounds of the group consisting of 4-thiouridine, isomaltitol, and uridine in the preparation of therapeutically effective compositions against acute or chronic inflammations, and/or problems in hemostasis related to platelet function, as well as a method for treatment of acute or chronic inflammations, and/or problems in hemostasis related to platelet function with the exception of the use of uridine in the treatment of inflammatory conditions caused by a bacterial infection.

1 . The use of one or more of the compounds of the group consisting of 4-thiouridine, isomaltitol, and uridine in the preparation of therapeutically effective compositions against acute or chronic inflammations, and/or problems in hemostasis related to platelet function, with the exception of the use of uridine in the treatment of inflammatory conditions caused by a bacterial infection.  
     
     
         2 . The use according to  claim 1 , wherein the therapeutically effective compound is 4-thiouridine.  
     
     
         3 . The use according to  claim 1 , wherein the therapeutically effective compound is isomaltitol.  
     
     
         4 . The use according to  claim 1 , wherein the therapeutically effective compound is uridine.  
     
     
         5 . The use according one or more of claims  1 - 4 , wherein the therapeutically effective dose is 1 to 100 mg per kg bodyweight.  
     
     
         6 . Method for treatment of acute or chronic inflammations, and/or problems in hemostasis related to platelet function, 
 characterized in that a therapeutically effective amount of one or more the of compounds of the group consisting of 4-thiouridine, isomaltitol, and uridine in the preparation of therapeutically effective compositions against acute or chronic inflammations with the exception of the use of uridine in the treatment of inflammatory conditions caused by a bacterial infection..    
     
     
         7 . Method according to  claim 6 , wherein the active compound is administered in such an amount that the serum concentration thereof is 0.1 to 100 mM.